Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO21 Highlights on nivo+ipi vs EXTREME in 1st-line high-risk SCCHN: The CheckMate 651 study

Athanassios Argiris reports on key results from ESMO Congress 2021 on LBA36 - CheckMate 651, a phase III trial of nivolumab/ipilimumab versus EXTREME regimen in first-line treatment of recurrent or metastatic SCCHN

20 Sep 2021  Proffered Paper session - Head and neck cancer, excl. thyroid

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.